Coronavirus (COVID-19) - Latest Information for Patients and Visitors

(La más reciente información para pacientes y visitantes)

 

Read Now (Lea ahora)
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease (OSCAR)

view all Clinical Trials

Overview

This is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related disease. Otilimab is a human monoclonal anti-GM-CSF antibody that has not previously been tested in participants with severe pulmonary COVID-19 related disease. The aim of this study is to evaluate the benefit-risk of a single infusion of otilimab in the treatment of patients with severe COVID-19 related pulmonary disease. The study population will consist of hospitalized participants with new onset hypoxia requiring significant oxygen support or requiring early invasive mechanical ventilation (less than or equal to [<=] 48 hours before dosing). Participants will be randomized to receive a single intravenous (IV) infusion of otilimab or placebo, in addition to standard of care.

Contact

For more information about this trial or to inquire about eligibility, email breathe@tuhs.temple.edu or call 215-707-1359.